My last visits

NOVARTIS AG CHF NOVN Stock
Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Real-time Estimate Cboe Europe  -  03:17 2022-06-21 am EDT
80.18 CHF   +0.67%
06/20GLOBAL MARKETS LIVE : Airbus, Pfizer, Ryanair, NetEase, Novartis...
06/19CORRECTION : Novartis Faces $225 Million Lawsuit From Greek State Over Financing Of Doctors
MT
06/19Novartis Faces $221 Million Lawsuit From Greek State Over Financing Of Doctors
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Raised to Buy by Morgan Stanley

09/01/2020 | 08:43am EDT
share with twitter
share with LinkedIn
share with facebook

Morgan Stanley's analyst Mark Purcell has upgraded his rating from Neutral to Buy. The target price has been lifted and is now set at CHF 101 compared to CHF 93 before.


© MarketScreener with dpa-AFX Analyser 2020
All news about NOVARTIS AG
06/20GLOBAL MARKETS LIVE : Airbus, Pfizer, Ryanair, NetEase, Novartis...
06/19CORRECTION : Novartis Faces $225 Million Lawsuit From Greek State Over Financing Of Doctor..
MT
06/19Novartis Faces $221 Million Lawsuit From Greek State Over Financing Of Doctors
MT
06/17NOVARTIS : announces Nature Medicine publication of Zolgensma data demonstrating age-appro..
PU
06/17Novartis Unit Says EMA Accepts Generic Hyrimoz Filing for Review
MT
06/17Novartis Unit Seeks EU Nod for High Concentration Formula of Humira Biosimilar
MT
06/17Sandoz Application for proposed biosimilar adalimumab's high concentration formulation ..
GL
06/17Sandoz Application for proposed biosimilar adalimumab's high concentration formulation ..
AQ
06/17NOVARTIS : Sandoz Application for proposed biosimilar adalimumab's high concentration form..
DJ
06/16Pliant Therapeutics Earns $4 Million Milestone Payment Under Novartis Deal
MT
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 783 M - -
Net income 2022 9 470 M - -
Net Debt 2022 7 480 M - -
P/E ratio 2022 19,0x
Yield 2022 4,02%
Capitalization 179 B 179 B -
EV / Sales 2022 3,53x
EV / Sales 2023 3,39x
Nbr of Employees 110 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,40 $
Average target price 94,34 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-0.80%178 967
JOHNSON & JOHNSON-0.94%445 917
ELI LILLY AND COMPANY5.31%261 856
PFIZER, INC.-21.20%261 075
ROCHE HOLDING AG-19.98%254 731
ABBVIE INC.2.13%244 356